Archives

Loading Events

Major Depressive Disorder In Chronic Kidney Disease – Limited Access

The burden of Chronic Kidney Disease (CKD) for patients is multifactorial, including having psychiatric consequences such as Major Depressive Disorder (MDD). While the interplay between the two is not clearly defined, both CKD and MDD can impact medical outcomes. In this discussion, Dr. Green and Dr. Meyer will discuss the challenges and opportunities for patients with these comorbid conditions.

Speakers are employees for Otsuka Pharmaceutical Development & Commercialization, Inc.

This event is Private.
Featured Speakers
Jill A Green

Jill A Green, PhD

Nephrology Clinical & Scientific Director
    Otsuka Pharmaceutical Development & Commercialization, Inc.*

Jill A Green, PhD, is a Senior Medical Science Liaison in the nephrology division at Otsuka Pharmaceutical Development & Commercialization, Inc. Dr Green received her PhD in biomedical sciences, with a specialization in biochemical and molecular basis of disease. She went on to hold a research scientist role at The James Comprehensive Cancer Center at The Ohio State University, specializing in oncology pre-clinical research before taking a position as a Regulatory Compliance Officer where she managed thoracic oncology clinical trials at The James Cancer Hospital.

Dr Green has been a proud member of the PKD Foundation – Columbus, OH chapter for over 12 years where she has been active in fundraising and advocacy efforts.

Chip Meyer

Chip Meyer, PhD

Senior Medical Science Liaison
    Otsuka Pharmaceutical Development & Commercialization, Inc.*

Chip Meyer, PhD, is a Senior Medical Science Liaison in the neuroscience division at Otsuka Pharmaceutical Development & Commercialization, Inc. Dr. Meyer received hisPhD in Behavioral Neuroscience and Psychopharmacology from the University of Kentucky where he conducted pre-clinical research and drug development in the area of substance use disorders. He went on to complete a postdoctoral fellowship in Human BehavioralPharmacology at the University of Vermont where he conducted clinical research in substance use disorders.